menu
    • menu
    [{"orgOrder":0,"company":"Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UKRAINE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"DreamTec Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ Inapplicable"},{"orgOrder":0,"company":"DreamTec Research","sponsor":"DreamTec Cytokine Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Bacillus Subtilis Spore Extract","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ DreamTec Cytokine Limited","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ DreamTec Cytokine Limited"},{"orgOrder":0,"company":"DreamTec Research","sponsor":"Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DreamTec Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DreamTec Research \/ Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"DreamTec Research \/ Middle East Cell and Gene Therapy | National Institute of Genetic Engineering and Biotechnology"},{"orgOrder":0,"company":"FEMPHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HUNGARY","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Juvia","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"FEMPHARMA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Vaginal Gel","sponsorNew":"FEMPHARMA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"FEMPHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Replicor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"REP 2139","moa":"HBV RNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Replicor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Replicor \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Replicor \/ Inapplicable"},{"orgOrder":0,"company":"Archivel Farma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RUTI Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Archivel Farma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Archivel Farma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Archivel Farma \/ Inapplicable"},{"orgOrder":0,"company":"University of Arizona","sponsor":"Sunshine Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Arizona \/ Sunshine Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Arizona \/ Sunshine Biopharma"},{"orgOrder":0,"company":"BioDuro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BioDuro","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"BioDuro \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"BioDuro \/ Inapplicable"},{"orgOrder":0,"company":"Mercaptor Discoveries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mercaptor Discoveries","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Mercaptor Discoveries \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mercaptor Discoveries \/ Inapplicable"},{"orgOrder":0,"company":"ThermoGenesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ThermoGenesis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ThermoGenesis \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ThermoGenesis \/ Inapplicable"},{"orgOrder":0,"company":"Xencor","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Xencor \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Xencor \/ Vir Biotechnology"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Buccal","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Buccal","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"University of Georgia","sponsor":"CEL-SCI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Georgia \/ CEL-SCI","highestDevelopmentStatusID":"1","companyTruncated":"University of Georgia \/ CEL-SCI"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"University of Illinois","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Illinois","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Illinois \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Illinois \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"Medical University of Vienna","sponsor":"Viravaxx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Azithromycin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Vienna","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Medical University of Vienna \/ Viravaxx","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Vienna \/ Viravaxx"},{"orgOrder":0,"company":"VIB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"VIB \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"VIB \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Virna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Toronto \/ Virna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"University of Toronto \/ Virna Therapeutics"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Institut Pasteur Shanghai","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Alphamab Oncology \/ Institut Pasteur Shanghai","highestDevelopmentStatusID":"1","companyTruncated":"Alphamab Oncology \/ Institut Pasteur Shanghai"},{"orgOrder":0,"company":"East China Normal University","sponsor":"ImmuneCyte Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"East China Normal University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"East China Normal University \/ ImmuneCyte Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"East China Normal University \/ ImmuneCyte Life Sciences"},{"orgOrder":0,"company":"Institute of Microbiology of the Chinese Academy of Sciences","sponsor":"Shanghai Junshi Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Microbiology of the Chinese Academy of Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Institute of Microbiology of the Chinese Academy of Sciences \/ Shanghai Junshi Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Microbiology of the Chinese Academy of Sciences \/ Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanyou Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Sanyou Biopharmaceuticals \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"Sino Biological","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sino Biological","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sino Biological \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"Sino Biological \/ GeoVax Labs"},{"orgOrder":0,"company":"Tianjin University","sponsor":"Beroni Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Tianjin University \/ Beroni Group","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin University \/ Beroni Group"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"WuXi Biologics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Inapplicable"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"WuXi Biologics \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Vir Biotechnology"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"SuperTrans Medical","sponsor":"Mediforum Pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SuperTrans Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"SuperTrans Medical \/ Mediforum Pharm","highestDevelopmentStatusID":"1","companyTruncated":"SuperTrans Medical \/ Mediforum Pharm"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Aligos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Luxna Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Luxna Biotech \/ Aligos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Luxna Biotech \/ Aligos Therapeutics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Green Cross Lab Cell \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Green Cross Lab Cell \/ Kleo Pharmaceuticals"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"OliX Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"OliX Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Diamond Light Source","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Diamond Light Source","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Diamond Light Source \/ Exscientia","highestDevelopmentStatusID":"1","companyTruncated":"Diamond Light Source \/ Exscientia"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Imperial College London \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ Inapplicable"},{"orgOrder":0,"company":"RQ Bio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"RQ Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"RQ Bio \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"RQ Bio \/ AstraZeneca"},{"orgOrder":0,"company":"University of Birmingham","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"University of Birmingham \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Birmingham \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Serum Institute of India \/ Codagenix","highestDevelopmentStatusID":"1","companyTruncated":"Serum Institute of India \/ Codagenix"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Buccal","sponsorNew":"Emergent BioSolutions \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Emergent BioSolutions \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Emergent BioSolutions \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Emergent BioSolutions \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Alnylam Pharmaceuticals \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Alnylam Pharmaceuticals \/ Vir Biotechnology"},{"orgOrder":0,"company":"Biogen","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Biogen \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Biogen \/ Vir Biotechnology"},{"orgOrder":0,"company":"Continuus Pharmaceuticals","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Continuus Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Buccal","sponsorNew":"Continuus Pharmaceuticals \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Continuus Pharmaceuticals \/ Department of Defense"},{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Enanta Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Enanta Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Generation Bio \/ Vir Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Generation Bio \/ Vir Biotechnology"},{"orgOrder":0,"company":"Celularity","sponsor":"Kleo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celularity","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Celularity \/ Kleo Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Celularity \/ Kleo Pharmaceuticals"},{"orgOrder":0,"company":"Chromocell Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chromocell Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Chromocell Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Chromocell Corporation \/ Inapplicable"},{"orgOrder":0,"company":"A2A Pharmaceuticals","sponsor":"LAXAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"A2A Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"A2A Pharmaceuticals \/ LAXAI Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"A2A Pharmaceuticals \/ LAXAI Life Sciences"},{"orgOrder":0,"company":"Evonik","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Evonik","amount2":0.22,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.22,"dosageForm":"Buccal","sponsorNew":"Evonik \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Evonik \/ BARDA"},{"orgOrder":0,"company":"OntoChem","sponsor":"Anixa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"OntoChem","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"OntoChem \/ Anixa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"OntoChem \/ Anixa Biosciences"},{"orgOrder":0,"company":"Vopec Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vopec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vopec Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vopec Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"iBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"iBio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ Inapplicable"},{"orgOrder":0,"company":"Macromoltek","sponsor":"Cytovia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Macromoltek","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Macromoltek \/ Cytovia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Macromoltek \/ Cytovia Therapeutics"},{"orgOrder":0,"company":"Southwest Research Institute","sponsor":"Henry M. Jackson Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southwest Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Southwest Research Institute \/ Henry M. Jackson Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Southwest Research Institute \/ Henry M. Jackson Foundation"},{"orgOrder":0,"company":"Vyripharm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vyripharm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Vyripharm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vyripharm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Virginia Commonwealth University","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Virginia Commonwealth University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Virginia Commonwealth University \/ Hoth Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Virginia Commonwealth University \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Kaiser Permanente Washington Health Research","sponsor":"Civica Rx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kaiser Permanente Washington Health Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Kaiser Permanente Washington Health Research \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Kaiser Permanente Washington Health Research \/ Civica Rx"},{"orgOrder":0,"company":"Undisclosed","sponsor":"AIkido Pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"Undisclosed \/ AIkido Pharm","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ AIkido Pharm"},{"orgOrder":0,"company":"Max Planck Institute for Infection Biology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VPM1002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Max Planck Institute for Infection Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Max Planck Institute for Infection Biology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Max Planck Institute for Infection Biology \/ Inapplicable"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Institut Pasteur du Cambodge | Institut Pasteur de Madagascar","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Institut Pasteur \/ Institut Pasteur du Cambodge | Institut Pasteur de Madagascar","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ Institut Pasteur du Cambodge | Institut Pasteur de Madagascar"},{"orgOrder":0,"company":"Zosano Pharma","sponsor":"Gylden Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"CD8+ T Cell Adaptive Vaccine","moa":"CD8","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zosano Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Microneedle Patch","sponsorNew":"Zosano Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"1","companyTruncated":"Zosano Pharma \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"University of Exeter Medical School","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Exeter Medical School","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"University of Exeter Medical School \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Exeter Medical School \/ Inapplicable"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Baylor College of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Murdoch Children\u2019s Research Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Murdoch Children\u2019s Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal","sponsorNew":"Murdoch Children\u2019s Research Institute \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Murdoch Children\u2019s Research Institute \/ Inapplicable"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Abnova","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaJet \/ Abnova","highestDevelopmentStatusID":"1","companyTruncated":"PharmaJet \/ Abnova"},{"orgOrder":0,"company":"NanoPass Technologies","sponsor":"YNC Medical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NanoPass Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"NanoPass Technologies \/ YNC Medical","highestDevelopmentStatusID":"1","companyTruncated":"NanoPass Technologies \/ YNC Medical"},{"orgOrder":0,"company":"EpiVax","sponsor":"Immunomic Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Nucleic acid Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"EpiVax \/ Immunomic Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ Immunomic Therapeutics"},{"orgOrder":0,"company":"PharmaJet","sponsor":"USAID","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Fractional Inactivated Poliovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaJet \/ USAID","highestDevelopmentStatusID":"1","companyTruncated":"PharmaJet \/ USAID"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SARS-CoV-2 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"AIM Vaccine \/ The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ The First Affiliated Hospital of Bengbu Medical University | Ningbo Rongan Biological Pharmaceutical"},{"orgOrder":0,"company":"Auro Vaccines","sponsor":"Hilleman Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Auro Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Auro Vaccines \/ Hilleman Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Auro Vaccines \/ Hilleman Laboratories"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BBV152","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"International Centre for Diarrhoeal Disease Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"International Centre for Diarrhoeal Disease Research \/ Bharat Biotech","highestDevelopmentStatusID":"1","companyTruncated":"International Centre for Diarrhoeal Disease Research \/ Bharat Biotech"},{"orgOrder":0,"company":"Binex","sponsor":"Genexine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"GX-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Binex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Binex \/ Genexine","highestDevelopmentStatusID":"1","companyTruncated":"Binex \/ Genexine"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Omicron BA.4\/5-Delta Recombinant Protein COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ Inapplicable"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Omicron BA.4\/5-Delta Recombinant Protein COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ Inapplicable"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"TriLink BioTechnologies \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"TriLink BioTechnologies \/ Department of Defense"},{"orgOrder":0,"company":"Chumakov Federal Scientific Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chumakov Federal Scientific Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Chumakov Federal Scientific Center \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Chumakov Federal Scientific Center \/ Inapplicable"},{"orgOrder":0,"company":"The Chumakov Federal Scientific Center","sponsor":"Vektor State Research Center Of Virology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Whole-Virion Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Chumakov Federal Scientific Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"The Chumakov Federal Scientific Center \/ Vektor State Research Center Of Virology","highestDevelopmentStatusID":"1","companyTruncated":"The Chumakov Federal Scientific Center \/ Vektor State Research Center Of Virology"},{"orgOrder":0,"company":"Rochester Clinical Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rochester Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Rochester Clinical Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Rochester Clinical Research \/ Inapplicable"},{"orgOrder":0,"company":"Sechenov University Center for Clinical Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sechenov University Center for Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Solution","sponsorNew":"Sechenov University Center for Clinical Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sechenov University Center for Clinical Research \/ Inapplicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Serum Institute of India \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IC14","moa":"Monocyte differentiation antigen CD14","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Implicit Bioscience \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Implicit Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Implicit Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"IC14","moa":"Monocyte differentiation antigen CD14","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Implicit Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Implicit Bioscience \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Implicit Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Rasna Therapeutics","sponsor":"Tiziana Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Acquisition","leadProduct":"Dactinomycin","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rasna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Rasna Therapeutics \/ Tiziana Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Rasna Therapeutics \/ Tiziana Life Sciences"},{"orgOrder":0,"company":"Adrenomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Adrecizumab","moa":"ADM","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adrenomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adrenomed \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Adrenomed \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast International S\u00e0rl","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mesoblast International S\u00e0rl","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast International S\u00e0rl \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mesoblast International S\u00e0rl \/ Inapplicable"},{"orgOrder":0,"company":"ImStem Biotechnology","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"IMS001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImStem Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ImStem Biotechnology \/ AgeX Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"ImStem Biotechnology \/ AgeX Therapeutics"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Vaibhav Mokashi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Vaibhav Mokashi","highestDevelopmentStatusID":"1","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Vaibhav Mokashi"},{"orgOrder":0,"company":"Meridian IT","sponsor":"Mateon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"Trabedersen","moa":"Transforming growth factor beta-2 mRNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Meridian IT","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Meridian IT \/ Mateon Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Meridian IT \/ Mateon Therapeutics"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cidara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cidara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"UCLA Jonsson Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berzosertib","moa":"Serine-protein kinase ATR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck Group \/ UCLA Jonsson Comprehensive Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"Merck Group \/ UCLA Jonsson Comprehensive Cancer Center"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"NICHD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institutes of Health \/ NICHD","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ NICHD"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Israeli Phage Therapy Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Adaptive Phage Therapeutics \/ Israeli Phage Therapy Center","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive Phage Therapeutics \/ Israeli Phage Therapy Center"},{"orgOrder":0,"company":"GigaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GigaGen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GigaGen \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GigaGen \/ Inapplicable"},{"orgOrder":0,"company":"UCLA","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"UCLA","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"UCLA \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"UCLA \/ National Institutes of Health"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vir Biotechnology","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Vir Biotechnology \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Vir Biotechnology \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"University of Nebraska Medical Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Nebraska Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"University of Nebraska Medical Center \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Nebraska Medical Center \/ Inapplicable"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Research Center","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fred Hutchinson Cancer Research Center","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Fred Hutchinson Cancer Research Center \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Fred Hutchinson Cancer Research Center \/ National Institutes of Health"},{"orgOrder":0,"company":"Wuhan Union Hospital","sponsor":"Wuhan Hamilton Bio-technology Co., Ltd, China.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Wuhan Union Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Wuhan Union Hospital \/ Wuhan Hamilton Bio-technology Co., Ltd, China.","highestDevelopmentStatusID":"1","companyTruncated":"Wuhan Union Hospital \/ Wuhan Hamilton Bio-technology Co., Ltd, China."},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Cardiosphere-derived Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tianjin Tasly Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Tasly Group \/ Inapplicable"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"T89","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tianjin Tasly Group \/ Tianjin Tasly Group","highestDevelopmentStatusID":"1","companyTruncated":"Tianjin Tasly Group \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Lundquist Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lundquist Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lundquist Institute \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Lundquist Institute \/ Inapplicable"},{"orgOrder":0,"company":"Reig Jofre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Manremyc","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Reig Jofre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reig Jofre \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Reig Jofre \/ Inapplicable"},{"orgOrder":0,"company":"Ogevity Therapeutics, Inc.","sponsor":"National University of Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Reduxium","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ogevity Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Ogevity Therapeutics, Inc. \/ National University of Singapore","highestDevelopmentStatusID":"1","companyTruncated":"Ogevity Therapeutics, Inc. \/ National University of Singapore"},{"orgOrder":0,"company":"National Cheng-Kung University Hospital","sponsor":"Grape King Bio Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Troches","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Cheng-Kung University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"National Cheng-Kung University Hospital \/ Grape King Bio Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"National Cheng-Kung University Hospital \/ Grape King Bio Ltd."},{"orgOrder":0,"company":"Sao Thai Duong","sponsor":"Big Leap Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Kovir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sao Thai Duong","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sao Thai Duong \/ Big Leap Research","highestDevelopmentStatusID":"1","companyTruncated":"Sao Thai Duong \/ Big Leap Research"},{"orgOrder":0,"company":"Sao Thai Duong","sponsor":"Big Leap Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Kovir","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sao Thai Duong","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sao Thai Duong \/ Big Leap Research","highestDevelopmentStatusID":"1","companyTruncated":"Sao Thai Duong \/ Big Leap Research"},{"orgOrder":0,"company":"University of Maryland, Baltimore","sponsor":"OrthoCarolina Research Institute | University of Arkansas | OrthoMichigan | NYU School of Medicine | Sinai Hospital | MedStar Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Maryland, Baltimore","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Maryland, Baltimore \/ OrthoCarolina Research Institute | University of Arkansas | OrthoMichigan | NYU School of Medicine | Sinai Hospital | MedStar Health","highestDevelopmentStatusID":"1","companyTruncated":"University of Maryland, Baltimore \/ OrthoCarolina Research Institute | University of Arkansas | OrthoMichigan | NYU School of Medicine | Sinai Hospital | MedStar Health"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Food Supplement","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AB Biotics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ Inapplicable"},{"orgOrder":0,"company":"Renmin Hospital of Wuhan University","sponsor":"Ansun Biopharm","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"DAS181","moa":"Sialoglycans | Glycosaminoglycans","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Renmin Hospital of Wuhan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Nebulizer","sponsorNew":"Renmin Hospital of Wuhan University \/ Ansun Biopharm","highestDevelopmentStatusID":"1","companyTruncated":"Renmin Hospital of Wuhan University \/ Ansun Biopharm"},{"orgOrder":0,"company":"AntiCancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Methioninase","moa":"DNA methylation","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AntiCancer","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AntiCancer \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AntiCancer \/ Inapplicable"},{"orgOrder":0,"company":"AntiCancer","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Methioninase","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AntiCancer","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"AntiCancer \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AntiCancer \/ Inapplicable"},{"orgOrder":0,"company":"First Affiliated Hospital of Zhejiang University","sponsor":"Ascletis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASC09","moa":"HIV-1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"First Affiliated Hospital of Zhejiang University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"First Affiliated Hospital of Zhejiang University \/ Ascletis Pharma","highestDevelopmentStatusID":"1","companyTruncated":"First Affiliated Hospital of Zhejiang University \/ Ascletis Pharma"},{"orgOrder":0,"company":"Aviron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aprotinin","moa":"Plasma kallikrein | Plasminogen","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aviron","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Aviron \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Aviron \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Public Health Clinical Center","sponsor":"Kunming Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Shanghai Public Health Clinical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shanghai Public Health Clinical Center \/ Kunming Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Public Health Clinical Center \/ Kunming Pharmaceuticals"},{"orgOrder":0,"company":"Vedic Lifesciences Pvt. Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"5-aminolevulinic Acid Phosphate","moa":"Photosensitiser","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vedic Lifesciences Pvt. Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vedic Lifesciences Pvt. Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences Pvt. Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Trutag Technologies | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Brigham and Women's Hospital \/ Trutag Technologies | Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Brigham and Women's Hospital \/ Trutag Technologies | Gilead Sciences"},{"orgOrder":0,"company":"TriHealth","sponsor":"DoNotAge.org","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"TriHealth \/ DoNotAge.org","highestDevelopmentStatusID":"1","companyTruncated":"TriHealth \/ DoNotAge.org"},{"orgOrder":0,"company":"Profounda Pharmaceuticals","sponsor":"Knight Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Miltefosine","moa":"phosphoro-derivatives","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Profounda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Profounda Pharmaceuticals \/ Knight Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Profounda Pharmaceuticals \/ Knight Therapeutics"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Imperial College London \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ Inapplicable"},{"orgOrder":0,"company":"Keck Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Keck Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Keck Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Keck Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Primmune Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PRTX007","moa":"Toll-like-7 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Primmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Primmune Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Primmune Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Yale School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"||Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Yale School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Yale School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Yale School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Espero BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Espero BioPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Espero BioPharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Espero BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"TrippBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TD213","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TrippBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"TrippBio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TrippBio \/ Inapplicable"},{"orgOrder":0,"company":"TrippBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TD213","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TrippBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"TrippBio \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TrippBio \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DWN12088","moa":"Prolyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"KD Pharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"KD Pharma Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"KD Pharma Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"KD Pharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Mucokinetica","sponsor":"Covistat","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mucokinetica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mucokinetica \/ Covistat","highestDevelopmentStatusID":"1","companyTruncated":"Mucokinetica \/ Covistat"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"||Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Inapplicable"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly","highestDevelopmentStatusID":"1","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly"},{"orgOrder":0,"company":"University of Maryland School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Maryland School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Maryland School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Maryland School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Rising Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Minnesota \/ Rising Pharmaceuticals Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Minnesota \/ Rising Pharmaceuticals Inc"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Feinstein Institutes \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Feinstein Institutes \/ Inapplicable"},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lupus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lupus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Lupus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IRISYS, LLC","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"IRISYS, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"IRISYS, LLC \/ TFF Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"IRISYS, LLC \/ TFF Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Massachusetts General Hospital \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Massachusetts General Hospital \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"Lee Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"2-Deoxy-D-Glucose","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CSIR-Indian Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Sachet","sponsorNew":"CSIR-Indian Institute of Chemical Technology \/ Lee Pharma","highestDevelopmentStatusID":"1","companyTruncated":"CSIR-Indian Institute of Chemical Technology \/ Lee Pharma"},{"orgOrder":0,"company":"ViralClear Pharmaceuticals","sponsor":"Neuroclear","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Merimepodib","moa":"Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ViralClear Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ViralClear Pharmaceuticals \/ Neuroclear","highestDevelopmentStatusID":"1","companyTruncated":"ViralClear Pharmaceuticals \/ Neuroclear"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Moleculin Biotech","highestDevelopmentStatusID":"1","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Moleculin Biotech"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sihuan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"The University of Dundee","sponsor":"Insmed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Brensocatib","moa":"Dipeptidyl peptidase I","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Dundee","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Dundee \/ Insmed","highestDevelopmentStatusID":"1","companyTruncated":"The University of Dundee \/ Insmed"},{"orgOrder":0,"company":"The Himalaya Drug Company","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Guduchi","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Himalaya Drug Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Himalaya Drug Company \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"The Himalaya Drug Company \/ Inapplicable"},{"orgOrder":0,"company":"Brinton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Brinton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Brinton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Brinton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Institute of Chemical Technology","sponsor":"Lasa Supergenerics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Institute of Chemical Technology \/ Lasa Supergenerics","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Chemical Technology \/ Lasa Supergenerics"},{"orgOrder":0,"company":"Indian Council of Medical Research","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Indian Council of Medical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Indian Council of Medical Research \/ University of Oxford","highestDevelopmentStatusID":"1","companyTruncated":"Indian Council of Medical Research \/ University of Oxford"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Alchem International Private Ltd","sponsor":"AIIMS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Curcuminoid","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Alchem International Private Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Troche\/Lozenge","sponsorNew":"Alchem International Private Ltd \/ AIIMS","highestDevelopmentStatusID":"1","companyTruncated":"Alchem International Private Ltd \/ AIIMS"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Carragelose","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Marinomed Biotech \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"1","companyTruncated":"Marinomed Biotech \/ Austrian Research Promotion Agency"},{"orgOrder":0,"company":"Drug Innovation Ventures at Emory","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Drug Innovation Ventures at Emory","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Drug Innovation Ventures at Emory \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Drug Innovation Ventures at Emory \/ Inapplicable"},{"orgOrder":0,"company":"VERO Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VERO Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"VERO Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"VERO Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Taipei Medical University WanFang Hospital","sponsor":"Febico (Far East Bio-Tec Co Ltd)","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Spirulina","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Taipei Medical University WanFang Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taipei Medical University WanFang Hospital \/ Febico (Far East Bio-Tec Co Ltd)","highestDevelopmentStatusID":"1","companyTruncated":"Taipei Medical University WanFang Hospital \/ Febico (Far East Bio-Tec Co Ltd)"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kerry Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Inapplicable"},{"orgOrder":0,"company":"Bioithas SL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bioithas SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bioithas SL \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bioithas SL \/ Inapplicable"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Strain","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kerry Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Inapplicable"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Kerry Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kerry Group \/ Inapplicable"},{"orgOrder":0,"company":"Medi Pharma Vision","sponsor":"Veterinary Research Institute | Brno University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Smartprobio C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medi Pharma Vision","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medi Pharma Vision \/ Veterinary Research Institute | Brno University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Medi Pharma Vision \/ Veterinary Research Institute | Brno University Hospital"},{"orgOrder":0,"company":"Novozymes","sponsor":"Estimates OY","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Bacillus Velezensis DSM 33864","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novozymes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novozymes \/ Estimates OY","highestDevelopmentStatusID":"1","companyTruncated":"Novozymes \/ Estimates OY"},{"orgOrder":0,"company":"Min-Tze LIONG","sponsor":"International Islamic University Malaysia | Beijing Scitop Bio-Tech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Min-Tze LIONG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Min-Tze LIONG \/ International Islamic University Malaysia | Beijing Scitop Bio-Tech Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Min-Tze LIONG \/ International Islamic University Malaysia | Beijing Scitop Bio-Tech Co., Ltd."},{"orgOrder":0,"company":"University of Bari","sponsor":"Uni-Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactolevure","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Bari","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of Bari \/ Uni-Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Bari \/ Uni-Pharma"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Vedic Lifesciences Pvt. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Archer Daniels Midland \/ Vedic Lifesciences Pvt. Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Vedic Lifesciences Pvt. Ltd."},{"orgOrder":0,"company":"Ab-Biotics","sponsor":"Zambon Group SpA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"KABP022","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ab-Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ab-Biotics \/ Zambon Group SpA","highestDevelopmentStatusID":"1","companyTruncated":"Ab-Biotics \/ Zambon Group SpA"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Alpha-Lactalbumin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lo.Li.Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amarillo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Alpha","moa":"IFNAR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Amarillo Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amarillo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Amarillo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"INSERM | Versailles Saint Quentin en Yvelines University | Universit\u00e9 Paris-Saclay | Paris 12 Val de Marne University | Commissariat A L'energie Atomique | Beckman Coulter | Lumedix | Elice | Biothelis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"NR3C1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Versailles Saint Quentin en Yvelines University | Universit\u00e9 Paris-Saclay | Paris 12 Val de Marne University | Commissariat A L'energie Atomique | Beckman Coulter | Lumedix | Elice | Biothelis","highestDevelopmentStatusID":"1","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Versailles Saint Quentin en Yvelines University | Universit\u00e9 Paris-Saclay | Paris 12 Val de Marne University | Commissariat A L'energie Atomique | Beckman Coulter | Lumedix | Elice | Biothelis"},{"orgOrder":0,"company":"Ennaid Therapeutics","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ennaid Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ennaid Therapeutics \/ Strides Pharma Science","highestDevelopmentStatusID":"1","companyTruncated":"Ennaid Therapeutics \/ Strides Pharma Science"},{"orgOrder":0,"company":"Antabio","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Antabio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Antabio \/ CARB-X","highestDevelopmentStatusID":"1","companyTruncated":"Antabio \/ CARB-X"},{"orgOrder":0,"company":"Second Affiliated Hospital of Wenzhou Medical University","sponsor":"WanBangDe Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bromhexine Hydrochloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Second Affiliated Hospital of Wenzhou Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Second Affiliated Hospital of Wenzhou Medical University \/ WanBangDe Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Second Affiliated Hospital of Wenzhou Medical University \/ WanBangDe Pharmaceutical"},{"orgOrder":0,"company":"Regenexx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Platelet Lysate","moa":"Growth factor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Regenexx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Nebulizer","sponsorNew":"Regenexx \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Regenexx \/ Inapplicable"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"Jianmin Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Calculus Bovis Sativus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tongji Hospital \/ Jianmin Pharmaceutical Group","highestDevelopmentStatusID":"1","companyTruncated":"Tongji Hospital \/ Jianmin Pharmaceutical Group"},{"orgOrder":0,"company":"Gyeonggido Business and Science Accelerator","sponsor":"CINECA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen receptor beta","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Gyeonggido Business and Science Accelerator","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gyeonggido Business and Science Accelerator \/ CINECA","highestDevelopmentStatusID":"1","companyTruncated":"Gyeonggido Business and Science Accelerator \/ CINECA"},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Akers Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Premas Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Premas Biotech \/ Akers Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Premas Biotech \/ Akers Biosciences"},{"orgOrder":0,"company":"Southern Research","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Modified Horsepox Virus Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Southern Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Southern Research \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"1","companyTruncated":"Southern Research \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Modified Horsepox Virus Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Al-Azhar University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Egymedicalpedia \/ Al-Azhar University","highestDevelopmentStatusID":"1","companyTruncated":"Egymedicalpedia \/ Al-Azhar University"},{"orgOrder":0,"company":"ImmuPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Forigerimod","moa":"Heat shock cognate 71 kDa protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmuPharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ImmuPharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ImmuPharma \/ Inapplicable"},{"orgOrder":0,"company":"DelSiTech","sponsor":"DRW Venture Capital LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Entecavir","moa":"DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DelSiTech","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"DelSiTech \/ DRW Venture Capital LLC","highestDevelopmentStatusID":"1","companyTruncated":"DelSiTech \/ DRW Venture Capital LLC"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Ropeginterferon-Alfa-2b","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Taiwan University Hospital \/ PharmaEssentia","highestDevelopmentStatusID":"1","companyTruncated":"National Taiwan University Hospital \/ PharmaEssentia"},{"orgOrder":0,"company":"Beech Tree Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Thimerosal","moa":"anti-inflammatory agents (salicylic acid derivatives)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Beech Tree Labs","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sublingual Solution","sponsorNew":"Beech Tree Labs \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Beech Tree Labs \/ Inapplicable"},{"orgOrder":0,"company":"Huro Biotech","sponsor":"Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DSM32444","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Huro Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Huro Biotech \/ Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Huro Biotech \/ Thai Binh University of Medicine and Pharmacy"},{"orgOrder":0,"company":"Huro Biotech","sponsor":"Vietstar Biomedical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DSM32444","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Huro Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Huro Biotech \/ Vietstar Biomedical Research","highestDevelopmentStatusID":"1","companyTruncated":"Huro Biotech \/ Vietstar Biomedical Research"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Qatar University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Qatar University","highestDevelopmentStatusID":"1","companyTruncated":"Hamad Medical Corporation \/ Qatar University"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clofazimine","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"McMaster University","sponsor":"Physician Services Incorporated | Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"McMaster University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McMaster University \/ Physician Services Incorporated | Canadian Institutes of Health Research","highestDevelopmentStatusID":"1","companyTruncated":"McMaster University \/ Physician Services Incorporated | Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Manimarane Arjunan, MD,DM (Cardiology)","sponsor":"UR Anoop Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Manimarane Arjunan, MD,DM (Cardiology)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manimarane Arjunan, MD,DM (Cardiology) \/ UR Anoop Research Group","highestDevelopmentStatusID":"1","companyTruncated":"Manimarane Arjunan, MD,DM (Cardiology) \/ UR Anoop Research Group"},{"orgOrder":0,"company":"Medical Corps, Israel Defense Force","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical Corps, Israel Defense Force","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical Corps, Israel Defense Force \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Medical Corps, Israel Defense Force \/ Inapplicable"},{"orgOrder":0,"company":"ImmuneMed, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Virus Suppressing Factor","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmuneMed, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmuneMed, Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ImmuneMed, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Nascent Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pritumumab","moa":"Vimentin","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nascent Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nascent Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nascent Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Covimabs","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"SIWA Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SIWA 318H","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SIWA Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIWA Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"SIWA Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mabpharm","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"ACE-MAB","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mabpharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mabpharm \/ Sorrento Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mabpharm \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TAK-888","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TAK-888","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Dinona","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"DNP-019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Samsung Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samsung Biologics \/ Dinona","highestDevelopmentStatusID":"1","companyTruncated":"Samsung Biologics \/ Dinona"},{"orgOrder":0,"company":"Capricor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Cardiosphere-Derived Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Capricor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capricor \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Capricor \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast International S\u00e0rl","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mesoblast International S\u00e0rl","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast International S\u00e0rl \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mesoblast International S\u00e0rl \/ Inapplicable"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Hope Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HB-adMSC","moa":"Mesenchymal stem cells","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hope Biosciences \/ Hope Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Hope Biosciences \/ Hope Biosciences"},{"orgOrder":0,"company":"Pluri","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PLX Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pluri","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Pluri \/ Inapplicable"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"haNK","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NantKwest","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NantKwest \/ ImmunityBio","highestDevelopmentStatusID":"1","companyTruncated":"NantKwest \/ ImmunityBio"},{"orgOrder":0,"company":"Novellus","sponsor":"Novecite","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Induced Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novellus","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Novellus \/ Novecite","highestDevelopmentStatusID":"1","companyTruncated":"Novellus \/ Novecite"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Minnesota \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Minnesota \/ Inapplicable"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"EDV","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnGeneIC \/ ImmunityBio","highestDevelopmentStatusID":"1","companyTruncated":"EnGeneIC \/ ImmunityBio"},{"orgOrder":0,"company":"Cellenkos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CK0801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cellenkos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellenkos \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cellenkos \/ Inapplicable"},{"orgOrder":0,"company":"Signature Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cell","moa":"ACE2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Signature Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Signature Biologics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Signature Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"CHO-DG44","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aragen Life Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aragen Life Sciences \/ Serum Institute of India","highestDevelopmentStatusID":"1","companyTruncated":"Aragen Life Sciences \/ Serum Institute of India"},{"orgOrder":0,"company":"Transgene","sponsor":"Vaxxel","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"DuckCelt-T17","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ Vaxxel","highestDevelopmentStatusID":"1","companyTruncated":"Transgene \/ Vaxxel"},{"orgOrder":0,"company":"Reading Scientific Services","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Partnership","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Reading Scientific Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reading Scientific Services \/ Ethypharm","highestDevelopmentStatusID":"1","companyTruncated":"Reading Scientific Services \/ Ethypharm"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"INSERM | Commissariat A L'energie Atomique | Institut Pasteur","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Commissariat A L'energie Atomique | Institut Pasteur","highestDevelopmentStatusID":"1","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM | Commissariat A L'energie Atomique | Institut Pasteur"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Quadramune","moa":"NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Fiber","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Hofseth Biocare ASA","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hofseth Biocare ASA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hofseth Biocare ASA \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Hofseth Biocare ASA \/ KGK Science"},{"orgOrder":0,"company":"Obafemi Awolowo University","sponsor":"Borno State Ministry of Health | Ogun State Ministry of Health | Abia State Ministry of Health | Sokoto State Ministry of Health | Benue State Minsitry of Health | University of Calabar Teaching Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Obafemi Awolowo University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Obafemi Awolowo University \/ Borno State Ministry of Health | Ogun State Ministry of Health | Abia State Ministry of Health | Sokoto State Ministry of Health | Benue State Minsitry of Health | University of Calabar Teaching Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Obafemi Awolowo University \/ Borno State Ministry of Health | Ogun State Ministry of Health | Abia State Ministry of Health | Sokoto State Ministry of Health | Benue State Minsitry of Health | University of Calabar Teaching Hospital"},{"orgOrder":0,"company":"PiLeJe","sponsor":"Clinact | Clinfile","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Babybiane Imedia","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PiLeJe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PiLeJe \/ Clinact | Clinfile","highestDevelopmentStatusID":"1","companyTruncated":"PiLeJe \/ Clinact | Clinfile"},{"orgOrder":0,"company":"Zagazig University","sponsor":"Charles Drew University of Medicine and Science | University of California, Irvine | Daiwa Pharmaceutical Corporation Co, Ltd, Tokyo 154-0024 Japan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Biobran","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zagazig University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zagazig University \/ Charles Drew University of Medicine and Science | University of California, Irvine | Daiwa Pharmaceutical Corporation Co, Ltd, Tokyo 154-0024 Japan","highestDevelopmentStatusID":"1","companyTruncated":"Zagazig University \/ Charles Drew University of Medicine and Science | University of California, Irvine | Daiwa Pharmaceutical Corporation Co, Ltd, Tokyo 154-0024 Japan"},{"orgOrder":0,"company":"Hospital de Sagunto","sponsor":"Biopolis S.L. | Laboratorios Heel Espa\u00f1a","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hospital de Sagunto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital de Sagunto \/ Biopolis S.L. | Laboratorios Heel Espa\u00f1a","highestDevelopmentStatusID":"1","companyTruncated":"Hospital de Sagunto \/ Biopolis S.L. | Laboratorios Heel Espa\u00f1a"},{"orgOrder":0,"company":"Heinz Italia SpA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Heinz Italia SpA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heinz Italia SpA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Heinz Italia SpA \/ Inapplicable"},{"orgOrder":0,"company":"Saisei Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Saisei Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saisei Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Saisei Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Anewsha Therapeutics Inc.","sponsor":"University of Michigan | Biologics Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"CBDRA60","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anewsha Therapeutics Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anewsha Therapeutics Inc. \/ University of Michigan | Biologics Consulting","highestDevelopmentStatusID":"1","companyTruncated":"Anewsha Therapeutics Inc. \/ University of Michigan | Biologics Consulting"},{"orgOrder":0,"company":"AB Biotek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"ABBC1 Immunoessential","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AB Biotek","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"AB Biotek \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotek \/ Inapplicable"},{"orgOrder":0,"company":"Endourage, LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Formula C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Endourage, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endourage, LLC \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Endourage, LLC \/ Inapplicable"},{"orgOrder":0,"company":"Rutgers, The State University of New Jersey","sponsor":"Vault Health, Inc. | Danisco USA Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"OL-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rutgers, The State University of New Jersey","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers, The State University of New Jersey \/ Vault Health, Inc. | Danisco USA Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Rutgers, The State University of New Jersey \/ Vault Health, Inc. | Danisco USA Inc."},{"orgOrder":0,"company":"Fertypharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Fertybiotic Balance","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fertypharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fertypharm \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Fertypharm \/ Inapplicable"},{"orgOrder":0,"company":"University of Bari","sponsor":"Heinz Italia SpA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Milk Fermented with Lactobacillus Paracasei CBA L74","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Bari","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"University of Bari \/ Heinz Italia SpA","highestDevelopmentStatusID":"1","companyTruncated":"University of Bari \/ Heinz Italia SpA"},{"orgOrder":0,"company":"Fytexia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Verum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fytexia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fytexia \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Fytexia \/ Inapplicable"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Biogroup Laboratoire de biologie m\u00e9dicale","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Biogroup Laboratoire de biologie m\u00e9dicale","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ Biogroup Laboratoire de biologie m\u00e9dicale"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"H\u00f4pital Necker-Enfants Malades | Hospices Civils de Lyon | H\u00f4pital Universitaire Robert-Debr\u00e9 | Centre Hospitalier Intercommunal Creteil | Nantes University Hospital | R\u00e9seau ACTIV | H\u00f4pital Armand Trousseau | CHR - H\u00f4pital Roger Salengo | H\u00f4pital Nord - ","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ H\u00f4pital Necker-Enfants Malades | Hospices Civils de Lyon | H\u00f4pital Universitaire Robert-Debr\u00e9 | Centre Hospitalier Intercommunal Creteil | Nantes University Hospital | R\u00e9seau ACTIV | H\u00f4pital Armand Trousseau | CHR - H\u00f4pital Roger Salengo | H\u00f4pital Nord - ","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ H\u00f4pital Necker-Enfants Malades | Hospices Civils de Lyon | H\u00f4pital Universitaire Robert-Debr\u00e9 | Centre Hospitalier Intercommunal Creteil | Nantes University Hospital | R\u00e9seau ACTIV | H\u00f4pital Armand Trousseau | CHR - H\u00f4pital Roger Salengo | H\u00f4pital Nord - "},{"orgOrder":0,"company":"USANA Health Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"USANA Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"USANA Health Sciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"USANA Health Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Mount Sinai Hospital, Canada","sponsor":"Sault Area Hospital | Michael Garron Hospital | Unity Health Toronto | The Ottawa Hospital | Northwestern Memorial Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mount Sinai Hospital, Canada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mount Sinai Hospital, Canada \/ Sault Area Hospital | Michael Garron Hospital | Unity Health Toronto | The Ottawa Hospital | Northwestern Memorial Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Mount Sinai Hospital, Canada \/ Sault Area Hospital | Michael Garron Hospital | Unity Health Toronto | The Ottawa Hospital | Northwestern Memorial Hospital"},{"orgOrder":0,"company":"AronPharma Sp. z o. o.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"AP203","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AronPharma Sp. z o. o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AronPharma Sp. z o. o. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AronPharma Sp. z o. o. \/ Inapplicable"},{"orgOrder":0,"company":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n","sponsor":"SOLUTEX GC SL","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n \/ SOLUTEX GC SL","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigaci\u00f3n Sanitaria Arag\u00f3n \/ SOLUTEX GC SL"},{"orgOrder":0,"company":"CanXida","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Canxida Remove Formula Rmv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CanXida","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanXida \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"CanXida \/ Citruslabs"},{"orgOrder":0,"company":"Heilongjiang Feihe Dairy Co. Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Feihe Investigational Formula","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Heilongjiang Feihe Dairy Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Heilongjiang Feihe Dairy Co. Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Heilongjiang Feihe Dairy Co. Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Oystershell NV","sponsor":"Eurofins CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oystershell NV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oystershell NV \/ Eurofins CDMO","highestDevelopmentStatusID":"1","companyTruncated":"Oystershell NV \/ Eurofins CDMO"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Fatty acid synthase (FASN)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Oystershell NV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oystershell NV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Oystershell NV \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Oystershell NV \/ Inapplicable"},{"orgOrder":0,"company":"Catalysis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Viusid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalysis \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Catalysis \/ Inapplicable"},{"orgOrder":0,"company":"Pharmavite","sponsor":"Atlantia Food Clinical Trials Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pharmavite","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmavite \/ Atlantia Food Clinical Trials Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Pharmavite \/ Atlantia Food Clinical Trials Ltd."},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Pasteur \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ Inapplicable"},{"orgOrder":0,"company":"Comenius University","sponsor":"Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Comenius University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Comenius University \/ Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o.","highestDevelopmentStatusID":"1","companyTruncated":"Comenius University \/ Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o."},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Inapplicable"},{"orgOrder":0,"company":"Rigshospitalet","sponsor":"Innovation Fund Denmark","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"HPAPI","year":"2020","type":"Funding","leadProduct":"Iloprost","moa":"Prostanoid IP receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigshospitalet \/ Innovation Fund Denmark","highestDevelopmentStatusID":"1","companyTruncated":"Rigshospitalet \/ Innovation Fund Denmark"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Hanoi University of Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Spore","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Hanoi University of Science","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Hanoi University of Science"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Drugs For Neglected Disease Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Oligonucleotide","year":"2020","type":"Partnership","leadProduct":"CpG-D35","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Bio-Pharma \/ Drugs For Neglected Disease Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Bio-Pharma \/ Drugs For Neglected Disease Initiative"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Qingfeng Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Qingfeng Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bellerophon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Slovenian Society for Gastroenterology and Hepatology","sponsor":"Krka","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Slovenian Society for Gastroenterology and Hepatology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Slovenian Society for Gastroenterology and Hepatology \/ Krka","highestDevelopmentStatusID":"1","companyTruncated":"Slovenian Society for Gastroenterology and Hepatology \/ Krka"},{"orgOrder":0,"company":"Max Healthcare Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Max Healthcare Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Max Healthcare Institute \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Max Healthcare Institute \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios Qu\u00edmica Luar","sponsor":"National Council of Scientific Research, Argentina | Centro de Excelencia C\u00f3rdoba","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Laboratorios Qu\u00edmica Luar","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Qu\u00edmica Luar \/ National Council of Scientific Research, Argentina | Centro de Excelencia C\u00f3rdoba","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Qu\u00edmica Luar \/ National Council of Scientific Research, Argentina | Centro de Excelencia C\u00f3rdoba"},{"orgOrder":0,"company":"Henan Genuine Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azvudine","moa":"Replicase polyprotein 1ab | Reverse transcriptase | Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Henan Genuine Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henan Genuine Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Henan Genuine Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Terra Biological LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxaloacetate","moa":"Krebs cycle","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Terra Biological LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Terra Biological LLC \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Terra Biological LLC \/ Inapplicable"},{"orgOrder":0,"company":"Soroka University Medical Center","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pirfenidone","moa":"TNF","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Soroka University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soroka University Medical Center \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"1","companyTruncated":"Soroka University Medical Center \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Fisabio","sponsor":"Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz | Hospital Universitario General de Villalba | Hospital Universitario Infanta Elena | Hospital Universitario Virgen de la Arrixaca | Hospital Cl\u00ednico Universitario de Valencia | Dentaid","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fisabio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fisabio \/ Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz | Hospital Universitario General de Villalba | Hospital Universitario Infanta Elena | Hospital Universitario Virgen de la Arrixaca | Hospital Cl\u00ednico Universitario de Valencia | Dentaid","highestDevelopmentStatusID":"1","companyTruncated":"Fisabio \/ Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz | Hospital Universitario General de Villalba | Hospital Universitario Infanta Elena | Hospital Universitario Virgen de la Arrixaca | Hospital Cl\u00ednico Universitario de Valencia | Dentaid"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oromucosal Solution","sponsorNew":"Queen Mary University of London \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Queen Mary University of London \/ GSK"},{"orgOrder":0,"company":"Canisius-Wilhelmina Hospital","sponsor":"Kappa Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Vitamin K2","moa":"Trypanosoma Cruzipain (Trypano CYSP)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Canisius-Wilhelmina Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canisius-Wilhelmina Hospital \/ Kappa Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Canisius-Wilhelmina Hospital \/ Kappa Bioscience"},{"orgOrder":0,"company":"PPC Pharmaceuticals","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EZC Pak","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PPC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PPC Pharmaceuticals \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"PPC Pharmaceuticals \/ Citruslabs"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nova Scotia Health Authority \/ Inapplicable"},{"orgOrder":0,"company":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd","sponsor":"Health Poverty Action | Centre of Malariology Parasitology and Entomology, Department of Communicable Diseases Control, Ministry of Health, Lao PDR | National Centre for Parasitology, Entomology and Malaria Control, Cambodia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icaridin","moa":"Odorant binding protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd \/ Health Poverty Action | Centre of Malariology Parasitology and Entomology, Department of Communicable Diseases Control, Ministry of Health, Lao PDR | National Centre for Parasitology, Entomology and Malaria Control, Cambodia","highestDevelopmentStatusID":"1","companyTruncated":"Macfarlane Burnet Institute for Medical Research and Public Health Ltd \/ Health Poverty Action | Centre of Malariology Parasitology and Entomology, Department of Communicable Diseases Control, Ministry of Health, Lao PDR | National Centre for Parasitology, Entomology and Malaria Control, Cambodia"},{"orgOrder":0,"company":"Mead Johnson Nutrition","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mead Johnson Nutrition","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mead Johnson Nutrition \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Mead Johnson Nutrition \/ Inapplicable"},{"orgOrder":0,"company":"U.S. Army Medical Research and Development Command","sponsor":"SIGA Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"U.S. Army Medical Research and Development Command","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"U.S. Army Medical Research and Development Command \/ SIGA Technologies","highestDevelopmentStatusID":"1","companyTruncated":"U.S. Army Medical Research and Development Command \/ SIGA Technologies"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Valenta Pharm JSC \/ Inapplicable"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Peking Union Medical College Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Montefiore Medical Center","sponsor":"Westat | Massachusetts General Hospital | Truth Initiative | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Montefiore Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Montefiore Medical Center \/ Westat | Massachusetts General Hospital | Truth Initiative | National Cancer Institute","highestDevelopmentStatusID":"1","companyTruncated":"Montefiore Medical Center \/ Westat | Massachusetts General Hospital | Truth Initiative | National Cancer Institute"},{"orgOrder":0,"company":"Chengdu Zenitar Biomedical Technology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Flunotinib Maleate","moa":"VEGFR \/ PDGFR \/ FGFR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chengdu Zenitar Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chengdu Zenitar Biomedical Technology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Chengdu Zenitar Biomedical Technology \/ Inapplicable"},{"orgOrder":0,"company":"Ruijin Hospital","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tenofovir Amibufenamide","moa":"Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ruijin Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ruijin Hospital \/ Hansoh Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Ruijin Hospital \/ Hansoh Pharma"},{"orgOrder":0,"company":"Universitas Padjadjaran","sponsor":"National Research and Innovation Agency of Indonesia | Prodia Diacro Laboratories P.T.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Quinine Sulfate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Universitas Padjadjaran","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitas Padjadjaran \/ National Research and Innovation Agency of Indonesia | Prodia Diacro Laboratories P.T.","highestDevelopmentStatusID":"1","companyTruncated":"Universitas Padjadjaran \/ National Research and Innovation Agency of Indonesia | Prodia Diacro Laboratories P.T."},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"Kintampo Health Research Centre, Ghana","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sulfadoxine","moa":"Dihydropteroate synthetase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London School of Hygiene & Tropical Medicine \/ Kintampo Health Research Centre, Ghana","highestDevelopmentStatusID":"1","companyTruncated":"London School of Hygiene & Tropical Medicine \/ Kintampo Health Research Centre, Ghana"},{"orgOrder":0,"company":"Dentaid","sponsor":"Methodex","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cetylpyridinium Chloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dentaid","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"Dentaid \/ Methodex","highestDevelopmentStatusID":"1","companyTruncated":"Dentaid \/ Methodex"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Geistlich Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dental Gel","sponsorNew":"Queen Mary University of London \/ Geistlich Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Queen Mary University of London \/ Geistlich Pharma"},{"orgOrder":0,"company":"IRCCS San Raffaele","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"IRCCS San Raffaele","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRCCS San Raffaele \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"IRCCS San Raffaele \/ GSK"},{"orgOrder":0,"company":"Love Wellness","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Boric Acid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Love Wellness","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Love Wellness \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Love Wellness \/ Citruslabs"},{"orgOrder":0,"company":"Oystershell NV","sponsor":"Eurofins Dermscan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amorolfine Hydrochloride","moa":"squalene","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oystershell NV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oystershell NV \/ Eurofins Dermscan","highestDevelopmentStatusID":"1","companyTruncated":"Oystershell NV \/ Eurofins Dermscan"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Ontario HIV Treatment Network | Maple Leaf Research | Unity Health Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Efavirenz","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Toronto \/ Ontario HIV Treatment Network | Maple Leaf Research | Unity Health Toronto","highestDevelopmentStatusID":"1","companyTruncated":"University of Toronto \/ Ontario HIV Treatment Network | Maple Leaf Research | Unity Health Toronto"},{"orgOrder":0,"company":"Centro de Investigacao em Saude de Manhica","sponsor":"World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centro de Investigacao em Saude de Manhica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centro de Investigacao em Saude de Manhica \/ World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique","highestDevelopmentStatusID":"1","companyTruncated":"Centro de Investigacao em Saude de Manhica \/ World Health Organization (Mozambique) | National Malaria Control Program, Mozambique | Instituto Nacional de Sa\u00fade, Mozambique"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurinia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Aurinia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Darunavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dacomitinib","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-4 | Receptor protein-tyrosine kinase erbB-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Taiko Pharmaceutical","sponsor":"Kitasato University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chlorine Dioxide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Taiko Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Taiko Pharmaceutical \/ Kitasato University","highestDevelopmentStatusID":"1","companyTruncated":"Taiko Pharmaceutical \/ Kitasato University"},{"orgOrder":0,"company":"Pulmatrix","sponsor":"Sensory Cloud","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"PUR 003","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pulmatrix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Pulmatrix \/ Sensory Cloud","highestDevelopmentStatusID":"1","companyTruncated":"Pulmatrix \/ Sensory Cloud"},{"orgOrder":0,"company":"AIIMS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIIMS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AIIMS \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AIIMS \/ Inapplicable"},{"orgOrder":0,"company":"Turn Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Petrolatum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Turn Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Turn Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Turn Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"diABZI","moa":"STING","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Pennsylvania \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Pennsylvania \/ Inapplicable"},{"orgOrder":0,"company":"Emery Pharma","sponsor":"Halodine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Emery Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Emery Pharma \/ Halodine","highestDevelopmentStatusID":"1","companyTruncated":"Emery Pharma \/ Halodine"},{"orgOrder":0,"company":"Kerecis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ICELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omega3 Viruxide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kerecis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Kerecis \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kerecis \/ Inapplicable"},{"orgOrder":0,"company":"CARE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||Toll-like receptor 7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CARE","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARE \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CARE \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"European Health Authorities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ European Health Authorities","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ European Health Authorities"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Avivagen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Beta Carotene","moa":"arotinoid derivatives","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avivagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avivagen \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Avivagen \/ Inapplicable"},{"orgOrder":0,"company":"Covar Pharmaceuticals","sponsor":"Aptorum","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"SACT-COV19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Covar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Covar Pharmaceuticals \/ Aptorum","highestDevelopmentStatusID":"1","companyTruncated":"Covar Pharmaceuticals \/ Aptorum"},{"orgOrder":0,"company":"Zhongnan Hospital of Wuhan University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dipyridamole","moa":"Equilibrative nucleoside transporter 1 | 3',5'-cyclic phosphodiesterase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhongnan Hospital of Wuhan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhongnan Hospital of Wuhan University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhongnan Hospital of Wuhan University \/ Inapplicable"},{"orgOrder":0,"company":"Sesderma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sesderma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sesderma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sesderma \/ Inapplicable"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Erdosteine","moa":"Pancreatic elastase 1 (CELA1)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recipharm AB \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Recipharm AB \/ Inapplicable"},{"orgOrder":0,"company":"AI VIVO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Imatinib Mesylate","moa":"Stem cell growth factor receptor | Platelet-derived growth factor receptor beta | Bcr\/Abl fusion protein | Tyrosine-protein kinase ABL","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AI VIVO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AI VIVO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AI VIVO \/ Undisclosed"},{"orgOrder":0,"company":"Exvastat","sponsor":"Innovative Medicines Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Imatinib Mesylate","moa":"Stem cell growth factor receptor | Platelet-derived growth factor receptor beta | Bcr\/Abl fusion protein | Tyrosine-protein kinase ABL","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exvastat","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exvastat \/ Innovative Medicines Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Exvastat \/ Innovative Medicines Initiative"},{"orgOrder":0,"company":"GSK","sponsor":"Xiamen Innovax Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"AS03","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Xiamen Innovax Biotech","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ Xiamen Innovax Biotech"},{"orgOrder":0,"company":"Purdue University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Purdue University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Purdue University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Purdue University \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cipla \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cipla \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Senhwa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Silmitasertib","moa":"Casein kinase II alpha","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Senhwa Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Senhwa Biosciences"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biotron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cinnamoylguanidine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biotron","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotron \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Biotron \/ Inapplicable"},{"orgOrder":0,"company":"Novotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Panaphix","moa":"Cytokine","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Novotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Novotech \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ US Government","highestDevelopmentStatusID":"1","companyTruncated":"Bayer AG \/ US Government"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"||Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Inapplicable"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Inapplicable"},{"orgOrder":0,"company":"University Hospitals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cetylpyridinium Chloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University Hospitals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospitals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University Hospitals \/ Inapplicable"},{"orgOrder":0,"company":"Cascade Chemistry","sponsor":"Algernon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cascade Chemistry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cascade Chemistry \/ Algernon Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Cascade Chemistry \/ Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Corpometria Institute","sponsor":"Applied Biology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Dutasteride","moa":"||Steroid 5-alpha-reductase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Corpometria Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corpometria Institute \/ Applied Biology","highestDevelopmentStatusID":"1","companyTruncated":"Corpometria Institute \/ Applied Biology"},{"orgOrder":0,"company":"Dimerix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Propagermanium","moa":"quaternary ammonium derivatives","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dimerix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dimerix \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Dimerix \/ Inapplicable"},{"orgOrder":0,"company":"Inflammasome Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inflammasome Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Inflammasome Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Inflammasome Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"Sucrose Acetate Isobutyrate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Durect Corporation","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Durect Corporation \/ Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Durect Corporation \/ Gilead Sciences"},{"orgOrder":0,"company":"XBiotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"IH201","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XBiotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"XBiotech \/ Inapplicable"},{"orgOrder":0,"company":"EnteroBiotix","sponsor":"Thairm Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"EBX-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EnteroBiotix","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"EnteroBiotix \/ Thairm Bio","highestDevelopmentStatusID":"1","companyTruncated":"EnteroBiotix \/ Thairm Bio"},{"orgOrder":0,"company":"Codebase","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Codebase","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codebase \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Codebase \/ Inapplicable"},{"orgOrder":0,"company":"Somerset Pharmaceuticals Inc","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Sulfamethoxazole","moa":"||Bacterial dihydropteroate synthase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Somerset Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Somerset Pharmaceuticals Inc \/ Premier","highestDevelopmentStatusID":"1","companyTruncated":"Somerset Pharmaceuticals Inc \/ Premier"},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"KTH-222","moa":"MAPK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kalos Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kalos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kalos Therapeutics","sponsor":"Oncology Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"KTH-222","moa":"MAPK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kalos Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kalos Therapeutics \/ Oncology Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Kalos Therapeutics \/ Oncology Pharmaceuticals"},{"orgOrder":0,"company":"Federal Biomedical Agency of Russia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Leitragin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Federal Biomedical Agency of Russia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Federal Biomedical Agency of Russia \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Federal Biomedical Agency of Russia \/ Inapplicable"},{"orgOrder":0,"company":"SIRS Therapeutics","sponsor":"Wellington Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"FX06","moa":"Pro-inflammatory fibrin E1","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SIRS Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SIRS Therapeutics \/ Wellington Partners","highestDevelopmentStatusID":"1","companyTruncated":"SIRS Therapeutics \/ Wellington Partners"},{"orgOrder":0,"company":"University of Arkansas, Fayetteville","sponsor":"Ocean Spray, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Cranberry Juice","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Arkansas, Fayetteville","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Arkansas, Fayetteville \/ Ocean Spray, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"University of Arkansas, Fayetteville \/ Ocean Spray, Inc."},{"orgOrder":0,"company":"Kemin Foods LC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Whole Cell Algae Fermentate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kemin Foods LC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kemin Foods LC \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Kemin Foods LC \/ Inapplicable"},{"orgOrder":0,"company":"Biolab Sanus Farmaceutica","sponsor":"Medcin Instituto da Pele","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Stryphnodendron Adstringens Extract","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Biolab Sanus Farmaceutica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolab Sanus Farmaceutica \/ Medcin Instituto da Pele","highestDevelopmentStatusID":"1","companyTruncated":"Biolab Sanus Farmaceutica \/ Medcin Instituto da Pele"},{"orgOrder":0,"company":"Noos S.r.l.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri DSM 17938","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Noos S.r.l.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noos S.r.l. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Noos S.r.l. \/ Inapplicable"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiokid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ Inapplicable"},{"orgOrder":0,"company":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke \/ Lallemand Health Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Babyguard Breast Milk Probiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Biotic Sp. z o.o.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Nordic Biotic Sp. z o.o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nordic Biotic Sp. z o.o. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nordic Biotic Sp. z o.o. \/ Inapplicable"},{"orgOrder":0,"company":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","sponsor":"LALLEMAND HEALTH SOLUTIONS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke \/ Lallemand Health Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke \/ Lallemand Health Solutions"},{"orgOrder":0,"company":"AB Biotics","sponsor":"Innovacion y Desarrollo de Estrategias en Salud | Hospital General Dr. Manuel Gea Gonz\u00e1lez","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Biotics \/ Innovacion y Desarrollo de Estrategias en Salud | Hospital General Dr. Manuel Gea Gonz\u00e1lez","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ Innovacion y Desarrollo de Estrategias en Salud | Hospital General Dr. Manuel Gea Gonz\u00e1lez"},{"orgOrder":0,"company":"Universiti Kebangsaan Malaysia Medical Centre","sponsor":"Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Universiti Kebangsaan Malaysia Medical Centre","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universiti Kebangsaan Malaysia Medical Centre \/ Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia","highestDevelopmentStatusID":"1","companyTruncated":"Universiti Kebangsaan Malaysia Medical Centre \/ Y.S.P. Industries (M) Sdn. Bhd, Menara LGB, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Malaysia"},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"Atlantia Food Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Archer Daniels Midland \/ Atlantia Food Clinical Trials","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ Atlantia Food Clinical Trials"},{"orgOrder":0,"company":"Church & Dwight Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Limosilactobacillus Reuteri 3613","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Church & Dwight Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Church & Dwight Co \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Church & Dwight Co \/ Inapplicable"},{"orgOrder":0,"company":"Anabio R&D","sponsor":"Thai Binh University of Medicine and Pharmacy","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anabio R&D","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anabio R&D \/ Thai Binh University of Medicine and Pharmacy","highestDevelopmentStatusID":"1","companyTruncated":"Anabio R&D \/ Thai Binh University of Medicine and Pharmacy"},{"orgOrder":0,"company":"Mackay Memorial Hospital","sponsor":"Bened Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"PS23","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mackay Memorial Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mackay Memorial Hospital \/ Bened Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"Mackay Memorial Hospital \/ Bened Biomedical"},{"orgOrder":0,"company":"ProbiSearch SL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ProbiSearch SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProbiSearch SL \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ProbiSearch SL \/ Inapplicable"},{"orgOrder":0,"company":"National Children's Hospital, Vietnam","sponsor":"Anabio R&D","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Bacillus Subtilis","moa":"Bacteria microbiome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Children's Hospital, Vietnam","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Children's Hospital, Vietnam \/ Anabio R&D","highestDevelopmentStatusID":"1","companyTruncated":"National Children's Hospital, Vietnam \/ Anabio R&D"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"TCI Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Lactobacillus Johnsonii","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ TCI Co., Ltd.","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ TCI Co., Ltd."},{"orgOrder":0,"company":"Archer Daniels Midland","sponsor":"NEXT CRO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Multistrain Probiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Archer Daniels Midland","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Archer Daniels Midland \/ NEXT CRO","highestDevelopmentStatusID":"1","companyTruncated":"Archer Daniels Midland \/ NEXT CRO"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"TCI188","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Ibsa Probiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"IBSA Institut Biochimique \/ Inapplicable"},{"orgOrder":0,"company":"Happy V","sponsor":"Citruslabs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Prebiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Happy V","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Happy V \/ Citruslabs","highestDevelopmentStatusID":"1","companyTruncated":"Happy V \/ Citruslabs"},{"orgOrder":0,"company":"Synbio Tech Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"LP28","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Synbio Tech Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synbio Tech Inc. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Synbio Tech Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"University Hospital, Udine, Italy","sponsor":"Winclove Probiotics B.V. | Institut Allergosan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"OMNi-BiOTiC 41167","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University Hospital, Udine, Italy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Udine, Italy \/ Winclove Probiotics B.V. | Institut Allergosan","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital, Udine, Italy \/ Winclove Probiotics B.V. | Institut Allergosan"},{"orgOrder":0,"company":"Wecare Probiotics Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Wecare Probiotics Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wecare Probiotics Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Wecare Probiotics Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Culturelle Digestive Daily Probiotic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"Entera Health, Inc","sponsor":"Lemus Buhils, SL | Clinical Research Unit, IMIM","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Bovine Plasma-Derived Immunoglobulin Concentrate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Entera Health, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entera Health, Inc \/ Lemus Buhils, SL | Clinical Research Unit, IMIM","highestDevelopmentStatusID":"1","companyTruncated":"Entera Health, Inc \/ Lemus Buhils, SL | Clinical Research Unit, IMIM"},{"orgOrder":0,"company":"SPP Pharmaclon Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Polyferon","moa":"Interferon gamma receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SPP Pharmaclon Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SPP Pharmaclon Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"SPP Pharmaclon Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Henan Provincial People's Hospital","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Henan Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Henan Provincial People's Hospital \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Henan Provincial People's Hospital \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Swissx Labs AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Naja Venom","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Swissx Labs AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Swissx Labs AG \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Swissx Labs AG \/ Inapplicable"},{"orgOrder":0,"company":"Stanford Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Lambda","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Stanford Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Stanford Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Akron Biotech","sponsor":"Octapharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Partnership","leadProduct":"Virally Inactivated Human AB Serum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Akron Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akron Biotech \/ Octapharma","highestDevelopmentStatusID":"1","companyTruncated":"Akron Biotech \/ Octapharma"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Evasins","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ Inapplicable"},{"orgOrder":0,"company":"Entera Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"EnteraGam","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Entera Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entera Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Entera Health \/ Inapplicable"},{"orgOrder":0,"company":"NellOne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"NELL1","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NellOne Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NellOne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NellOne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"Radiolabelled MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Monopar Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"1","companyTruncated":"Monopar Therapeutics \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Felix Biotechnology","sponsor":"The National Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Felix Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Felix Biotechnology \/ The National Science Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Felix Biotechnology \/ The National Science Foundation"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive Phage Therapeutics \/ Department of Defense"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pfizer Inc","amount2":0.10000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"DNDi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Reddy\\'s Laboratories \/ DNDi","highestDevelopmentStatusID":"1","companyTruncated":"Dr. Reddy\\'s Laboratories \/ DNDi"},{"orgOrder":0,"company":"Codexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Codexis","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"Codexis \/ GSK"},{"orgOrder":0,"company":"Arranta Bio","sponsor":"Recipharm AB","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Arranta Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arranta Bio \/ Recipharm AB","highestDevelopmentStatusID":"1","companyTruncated":"Arranta Bio \/ Recipharm AB"},{"orgOrder":0,"company":"Plex Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Plex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Plex Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Plex Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Precisio Biotix Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precisio Biotix Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precisio Biotix Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"1","companyTruncated":"Precisio Biotix Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"Bactolife","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bactolife","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Bactolife \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Bactolife \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Harvard University","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Harvard University","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Harvard University \/ AbbVie Inc","highestDevelopmentStatusID":"1","companyTruncated":"Harvard University \/ AbbVie Inc"},{"orgOrder":0,"company":"iosBio","sponsor":"Department of Health and Social Care","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iosBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iosBio \/ Department of Health and Social Care","highestDevelopmentStatusID":"1","companyTruncated":"iosBio \/ Department of Health and Social Care"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Titan Pharmaceuticals Inc \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Ology Bioservices \/ Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ Department of Defense"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"TriLink BioTechnologies","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TriLink BioTechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriLink BioTechnologies \/ The International Vaccine Institute","highestDevelopmentStatusID":"1","companyTruncated":"TriLink BioTechnologies \/ The International Vaccine Institute"},{"orgOrder":0,"company":"AdventHealth","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SARSCoV2 Convalescent Plasma","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AdventHealth","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AdventHealth \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AdventHealth \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai BDgene Co., Ltd.","sponsor":"Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BD111","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Shanghai BDgene Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai BDgene Co., Ltd. \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai BDgene Co., Ltd. \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran"},{"orgOrder":0,"company":"The Herb, Inc","sponsor":"Prorelix Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Viracide","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Herb, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Herb, Inc \/ Prorelix Research","highestDevelopmentStatusID":"1","companyTruncated":"The Herb, Inc \/ Prorelix Research"},{"orgOrder":0,"company":"Universitas Padjadjaran","sponsor":"PT. Rhea Pharmaceutical Sciences Indonesia | Prodia Diacro Laboratories P.T.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Gardenia Jasminoides","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Universitas Padjadjaran","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitas Padjadjaran \/ PT. Rhea Pharmaceutical Sciences Indonesia | Prodia Diacro Laboratories P.T.","highestDevelopmentStatusID":"1","companyTruncated":"Universitas Padjadjaran \/ PT. Rhea Pharmaceutical Sciences Indonesia | Prodia Diacro Laboratories P.T."},{"orgOrder":0,"company":"\u00d6rebro University","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"L. reuteri DSM 17938","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"\u00d6rebro University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"\u00d6rebro University \/ BioGaia Pharma","highestDevelopmentStatusID":"1","companyTruncated":"\u00d6rebro University \/ BioGaia Pharma"},{"orgOrder":0,"company":"Tilman","sponsor":"Artialis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Nasafytol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tilman","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tilman \/ Artialis","highestDevelopmentStatusID":"1","companyTruncated":"Tilman \/ Artialis"},{"orgOrder":0,"company":"Imperial College London","sponsor":"hVIVO | Royal Free Hospital NHS FT","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Virus","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Imperial College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Imperial College London \/ hVIVO | Royal Free Hospital NHS FT","highestDevelopmentStatusID":"1","companyTruncated":"Imperial College London \/ hVIVO | Royal Free Hospital NHS FT"},{"orgOrder":0,"company":"ProbiSearch SL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lactobacillus Salivarius","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ProbiSearch SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProbiSearch SL \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ProbiSearch SL \/ Inapplicable"},{"orgOrder":0,"company":"DOMCA S.A.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Garlic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"DOMCA S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DOMCA S.A. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"DOMCA S.A. \/ Inapplicable"},{"orgOrder":0,"company":"SPP Pharmaclon Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Interferon gamma-1b","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SPP Pharmaclon Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"SPP Pharmaclon Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"SPP Pharmaclon Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Rothschild Foundation Hospital","sponsor":"Hotel Dieu Hospital | Institut Pasteur | Hopital Lariboisi\u00e8re","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RT-PCR SARS-CoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rothschild Foundation Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Swab","sponsorNew":"Rothschild Foundation Hospital \/ Hotel Dieu Hospital | Institut Pasteur | Hopital Lariboisi\u00e8re","highestDevelopmentStatusID":"1","companyTruncated":"Rothschild Foundation Hospital \/ Hotel Dieu Hospital | Institut Pasteur | Hopital Lariboisi\u00e8re"},{"orgOrder":0,"company":"John Hale","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"S. salivarius K12","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"John Hale","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"John Hale \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"John Hale \/ Inapplicable"},{"orgOrder":0,"company":"Oystershell NV","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"X92001752","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oystershell NV","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Shampoo","sponsorNew":"Oystershell NV \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Oystershell NV \/ Inapplicable"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XC8","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Valenta Pharm JSC \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SA58","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Sinovac Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sinovac Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Beijing Ditan Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SA58","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Sinovac Biotech \/ Beijing Ditan Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Sinovac Biotech \/ Beijing Ditan Hospital"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli | Gazi University | University of Alberta | Imperial College London | University of Debrecen | Lithuanian University of Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Fondazione Policlinico Universitario Agostino Gemelli | Gazi University | University of Alberta | Imperial College London | University of Debrecen | Lithuanian University of Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Fondazione Policlinico Universitario Agostino Gemelli | Gazi University | University of Alberta | Imperial College London | University of Debrecen | Lithuanian University of Health Sciences"},{"orgOrder":0,"company":"Chung Shan Medical University","sponsor":"Glory Kingdom Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Nettle","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chung Shan Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chung Shan Medical University \/ Glory Kingdom Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Chung Shan Medical University \/ Glory Kingdom Corporation"},{"orgOrder":0,"company":"Meiji China Investment Co.,Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Meiji Yogurt Group","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Meiji China Investment Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji China Investment Co.,Ltd \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Meiji China Investment Co.,Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Aterixen","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Valenta Pharm JSC \/ Inapplicable"},{"orgOrder":0,"company":"Vedic Lifesciences Pvt. Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Paractin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vedic Lifesciences Pvt. Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences Pvt. Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences Pvt. Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Vedic Lifesciences Pvt. Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Doctor\\'S Biome Medical Food","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vedic Lifesciences Pvt. Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences Pvt. Ltd. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences Pvt. Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Helmholtz Centre for Infection Research | GSK | University of Oxford | University of Cologne","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"C. Difficile Spore","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Leiden University Medical Center \/ Helmholtz Centre for Infection Research | GSK | University of Oxford | University of Cologne","highestDevelopmentStatusID":"1","companyTruncated":"Leiden University Medical Center \/ Helmholtz Centre for Infection Research | GSK | University of Oxford | University of Cologne"},{"orgOrder":0,"company":"University of Hong Kong","sponsor":"Sysmex Asia Pacific","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Sysmex UF-5000 system","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Hong Kong \/ Sysmex Asia Pacific","highestDevelopmentStatusID":"1","companyTruncated":"University of Hong Kong \/ Sysmex Asia Pacific"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MG1111","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"S-Trimer","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Clover Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kansas State University","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"TNX-2300","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Kansas State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kansas State University \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"1","companyTruncated":"Kansas State University \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Manhattan BioSolutions","sponsor":"Nascent Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Recombinant Mycobacterium Bovis Bacillus Calmette-Guerin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Manhattan BioSolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Manhattan BioSolutions \/ Nascent Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Manhattan BioSolutions \/ Nascent Biotech"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Expanded Collaboration","leadProduct":"CoV RBD219-N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CoV RBD219-N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Baylor College of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Merck & Co \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Genocea","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"GEN-003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Shionogi","highestDevelopmentStatusID":"1","companyTruncated":"Genocea \/ Shionogi"},{"orgOrder":0,"company":"Excivion","sponsor":"Coordination Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Zika-HX Antigen","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Excivion","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Excivion \/ CPI","highestDevelopmentStatusID":"1","companyTruncated":"Excivion \/ CPI"},{"orgOrder":0,"company":"Hospices Civils de Lyon","sponsor":"Biomerieux","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Virus-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"TTV DNAemia","moa":"TTV DNAemia","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Hospices Civils de Lyon","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospices Civils de Lyon \/ Biomerieux","highestDevelopmentStatusID":"1","companyTruncated":"Hospices Civils de Lyon \/ Biomerieux"},{"orgOrder":0,"company":"University of Louisville","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine","moa":"Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Louisville","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Louisville \/ Dynavax Technologies","highestDevelopmentStatusID":"1","companyTruncated":"University of Louisville \/ Dynavax Technologies"},{"orgOrder":0,"company":"Public health and reforms Center of Ministry of Health","sponsor":"World Health Organization | Ministry of Health of Azerbaijan Republic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Public health and reforms Center of Ministry of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Public health and reforms Center of Ministry of Health \/ World Health Organization | Ministry of Health of Azerbaijan Republic","highestDevelopmentStatusID":"1","companyTruncated":"Public health and reforms Center of Ministry of Health \/ World Health Organization | Ministry of Health of Azerbaijan Republic"},{"orgOrder":0,"company":"Vabiotech","sponsor":"Vietstar Biomedical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vabiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vabiotech \/ Vietstar Biomedical Research","highestDevelopmentStatusID":"1","companyTruncated":"Vabiotech \/ Vietstar Biomedical Research"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 mRNA Vaccine Bivalent","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Omicron BA.5 mRNA Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"AIM Vaccine \/ Ningbo Rongan Biological Pharmaceutical | The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Omicron-Delta COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"1","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"Ministry of Public Health, Argentina","sponsor":"Centers for Disease Control and Prevention | Pan American Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Yellow Fever Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ministry of Public Health, Argentina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ministry of Public Health, Argentina \/ Centers for Disease Control and Prevention | Pan American Health Organization","highestDevelopmentStatusID":"1","companyTruncated":"Ministry of Public Health, Argentina \/ Centers for Disease Control and Prevention | Pan American Health Organization"},{"orgOrder":0,"company":"VaxAlta","sponsor":"Scandinavian Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Campylobacter Jejuni Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VaxAlta","amount2":0.10000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"VaxAlta \/ Scandinavian Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"VaxAlta \/ Scandinavian Biopharma"},{"orgOrder":0,"company":"Acuitas","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-LNP Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Acuitas","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acuitas \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Acuitas \/ Pfizer Inc"},{"orgOrder":0,"company":"3PBiovian","sponsor":"SpyBiotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VLP Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"3PBiovian","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"3PBiovian \/ SpyBiotech","highestDevelopmentStatusID":"1","companyTruncated":"3PBiovian \/ SpyBiotech"},{"orgOrder":0,"company":"Vaxess","sponsor":"National Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vaxess","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Patch","sponsorNew":"Vaxess \/ National Science Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Vaxess \/ National Science Foundation"},{"orgOrder":0,"company":"Exyte","sponsor":"Univercells","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exyte","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Exyte \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"Exyte \/ Univercells"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Beijing ZhonghuaInvestment Fund Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generex Biotechnology","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Nasal","sponsorNew":"Generex Biotechnology \/ Beijing ZhonghuaInvestment Fund Management","highestDevelopmentStatusID":"1","companyTruncated":"Generex Biotechnology \/ Beijing ZhonghuaInvestment Fund Management"},{"orgOrder":0,"company":"Ology Bioservices","sponsor":"US Army Contracting Command","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ology Bioservices","amount2":0.11,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Nasal","sponsorNew":"Ology Bioservices \/ US Army Contracting Command","highestDevelopmentStatusID":"1","companyTruncated":"Ology Bioservices \/ US Army Contracting Command"},{"orgOrder":0,"company":"eTheRNA immunotherapies","sponsor":"LSP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2020","type":"Series B Financing","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"eTheRNA immunotherapies","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Nasal","sponsorNew":"eTheRNA immunotherapies \/ LSP","highestDevelopmentStatusID":"1","companyTruncated":"eTheRNA immunotherapies \/ LSP"},{"orgOrder":0,"company":"Dalton Pharma Services","sponsor":"VIDO-InterVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dalton Pharma Services","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Dalton Pharma Services \/ VIDO-InterVac","highestDevelopmentStatusID":"1","companyTruncated":"Dalton Pharma Services \/ VIDO-InterVac"},{"orgOrder":0,"company":"Chinese Academy of Sciences","sponsor":"Zhifei Longcom Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Chinese Academy of Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Chinese Academy of Sciences \/ Zhifei Longcom Biopharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Chinese Academy of Sciences \/ Zhifei Longcom Biopharmaceutical"},{"orgOrder":0,"company":"Fudan University","sponsor":"RNAcure Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fudan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Fudan University \/ RNAcure Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Fudan University \/ RNAcure Biopharma"},{"orgOrder":0,"company":"Tongji University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tongji University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tongji University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tongji University \/ Inapplicable"},{"orgOrder":0,"company":"AJ Vaccines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AJ Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"AJ Vaccines \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AJ Vaccines \/ Inapplicable"},{"orgOrder":0,"company":"ExpreS2ion Biotechnologies","sponsor":"The EU Horizon 2020 Consortium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ExpreS2ion Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 Consortium","highestDevelopmentStatusID":"1","companyTruncated":"ExpreS2ion Biotechnologies \/ The EU Horizon 2020 Consortium"},{"orgOrder":0,"company":"Institut Pasteur","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institut Pasteur","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Institut Pasteur \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pasteur \/ CEPI"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"MigVax","sponsor":"Ourcrowd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"MigVax","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Nasal","sponsorNew":"MigVax \/ Ourcrowd","highestDevelopmentStatusID":"1","companyTruncated":"MigVax \/ Ourcrowd"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"VLP Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"||SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Fujifilm holding \/ VLP Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm holding \/ VLP Therapeutics"},{"orgOrder":0,"company":"Coalition for Epidemic Preparedness Innovations","sponsor":"UK Governement","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Coalition for Epidemic Preparedness Innovations","amount2":0.27000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.27000000000000002,"dosageForm":"Nasal","sponsorNew":"Coalition for Epidemic Preparedness Innovations \/ UK Governement","highestDevelopmentStatusID":"1","companyTruncated":"Coalition for Epidemic Preparedness Innovations \/ UK Governement"},{"orgOrder":0,"company":"Russian Defence Ministry","sponsor":"National Research Center For Epidemiology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Russian Defence Ministry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Russian Defence Ministry \/ National Research Center For Epidemiology","highestDevelopmentStatusID":"1","companyTruncated":"Russian Defence Ministry \/ National Research Center For Epidemiology"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Themis Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ABL Bio \/ Themis Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"ABL Bio \/ Themis Bioscience"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"SK Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscience \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Celonic","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Celonic \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"Celonic \/ Intravacc"},{"orgOrder":0,"company":"COVAX Advance Market Commitment","sponsor":"Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"COVAX Advance Market Commitment","amount2":0.070000000000000007,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Nasal","sponsorNew":"COVAX Advance Market Commitment \/ Gates Foundation","highestDevelopmentStatusID":"1","companyTruncated":"COVAX Advance Market Commitment \/ Gates Foundation"},{"orgOrder":0,"company":"Neovii","sponsor":"Tel Aviv University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Neovii","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Neovii \/ Tel Aviv University","highestDevelopmentStatusID":"1","companyTruncated":"Neovii \/ Tel Aviv University"},{"orgOrder":0,"company":"WHO","sponsor":"Government of Belgium","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"WHO","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Nasal","sponsorNew":"WHO \/ Government of Belgium","highestDevelopmentStatusID":"1","companyTruncated":"WHO \/ Government of Belgium"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Governemnt of Mexico","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"World Health Organization","amount2":0.16,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.16,"dosageForm":"Nasal","sponsorNew":"World Health Organization \/ Governemnt of Mexico","highestDevelopmentStatusID":"1","companyTruncated":"World Health Organization \/ Governemnt of Mexico"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Japanese Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"World Health Organization","amount2":0.17000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.17000000000000001,"dosageForm":"Nasal","sponsorNew":"World Health Organization \/ Japanese Government","highestDevelopmentStatusID":"1","companyTruncated":"World Health Organization \/ Japanese Government"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Adimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Eden Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Eden Biologics \/ Adimmune","highestDevelopmentStatusID":"1","companyTruncated":"Eden Biologics \/ Adimmune"},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medigen Vaccine Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Medigen Vaccine Biologics \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Medigen Vaccine Biologics \/ National Institutes of Health"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"AstraZeneca \/ Barinthus Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"AstraZeneca \/ Barinthus Biotherapeutics"},{"orgOrder":0,"company":"Mynvax","sponsor":"Indian Institute of Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mynvax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Mynvax \/ Indian Institute of Science","highestDevelopmentStatusID":"1","companyTruncated":"Mynvax \/ Indian Institute of Science"},{"orgOrder":0,"company":"Tulane University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Tulane University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tulane University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Tulane University \/ Inapplicable"},{"orgOrder":0,"company":"Vibalogics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vibalogics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Vibalogics \/ Johnson & Johnson","highestDevelopmentStatusID":"1","companyTruncated":"Vibalogics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Adaptive Phage Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Nasal","sponsorNew":"Adaptive Phage Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Adaptive Phage Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"Flu Lab","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GreenLight Biosciences","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Nasal","sponsorNew":"GreenLight Biosciences \/ Flu Lab","highestDevelopmentStatusID":"1","companyTruncated":"GreenLight Biosciences \/ Flu Lab"},{"orgOrder":0,"company":"Croda","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Croda","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Croda \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Croda \/ Pfizer Inc"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":1,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":1,"dosageForm":"Nasal","sponsorNew":"Johnson & Johnson \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ BARDA"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Inovio Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Inovio Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Griffith University","sponsor":"Luina Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Griffith University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Griffith University \/ Luina Bio","highestDevelopmentStatusID":"1","companyTruncated":"Griffith University \/ Luina Bio"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Biological E","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Baylor College of Medicine \/ Biological E","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Biological E"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Baylor College of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"McKesson","sponsor":"Centers For Disease Control","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"McKesson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"McKesson \/ Centers For Disease Control","highestDevelopmentStatusID":"1","companyTruncated":"McKesson \/ Centers For Disease Control"},{"orgOrder":0,"company":"The Peter Doherty Institute","sponsor":"Jack Ma Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The Peter Doherty Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"The Peter Doherty Institute \/ Jack Ma Foundation","highestDevelopmentStatusID":"1","companyTruncated":"The Peter Doherty Institute \/ Jack Ma Foundation"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CEL-SCI \/ Inapplicable"},{"orgOrder":0,"company":"Institute for Systems Biology","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute for Systems Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Institute for Systems Biology \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Institute for Systems Biology \/ Merck & Co"},{"orgOrder":0,"company":"University of Wisconsin Madison","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CoroFlu Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Wisconsin Madison","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"University of Wisconsin Madison \/ Bharat Biotech","highestDevelopmentStatusID":"1","companyTruncated":"University of Wisconsin Madison \/ Bharat Biotech"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"University Of Natural Resources","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"S-Layer COVID Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Avalon GloboCare \/ University Of Natural Resources","highestDevelopmentStatusID":"1","companyTruncated":"Avalon GloboCare \/ University Of Natural Resources"},{"orgOrder":0,"company":"Avid Bioservices","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Terra CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Avid Bioservices","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avid Bioservices \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Avid Bioservices \/ Oragenics"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"CpG 1018","moa":"||Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0.080000000000000002,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ Cowen","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Technologies \/ Cowen"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Sinovac Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CpG 1018","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ Sinovac Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Technologies \/ Sinovac Biotech"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Valneva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"CpG 1018","moa":"||Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dynavax Technologies \/ Valneva","highestDevelopmentStatusID":"1","companyTruncated":"Dynavax Technologies \/ Valneva"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ii-Key Peptide Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generex Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Generex Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"NuGenerex","sponsor":"Bintai Kinden","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Ii-Key-SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NuGenerex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NuGenerex \/ Bintai Kinden","highestDevelopmentStatusID":"1","companyTruncated":"NuGenerex \/ Bintai Kinden"},{"orgOrder":0,"company":"University of the Witwatersrand","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ox1Cov-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of the Witwatersrand","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of the Witwatersrand \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"University of the Witwatersrand \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"The Department Of Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ The Department Of Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Zydus Lifesciences \/ The Department Of Biotechnology"},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Triple Antigen Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Premas Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Premas Biotech \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Premas Biotech \/ Inapplicable"},{"orgOrder":0,"company":"National Research Council of Canada","sponsor":"VBI Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Pan-Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"National Research Council of Canada","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Research Council of Canada \/ VBI Vaccines","highestDevelopmentStatusID":"1","companyTruncated":"National Research Council of Canada \/ VBI Vaccines"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"CanSino Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 mRNA-LNP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precision NanoSystems","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision NanoSystems \/ CanSino Biologics","highestDevelopmentStatusID":"1","companyTruncated":"Precision NanoSystems \/ CanSino Biologics"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"COVID-19 mRNA Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Precision NanoSystems","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Precision NanoSystems \/ Government of Canada","highestDevelopmentStatusID":"1","companyTruncated":"Precision NanoSystems \/ Government of Canada"},{"orgOrder":0,"company":"VIDO-InterVac","sponsor":"ZYUS Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Plant Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VIDO-InterVac","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIDO-InterVac \/ ZYUS Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"VIDO-InterVac \/ ZYUS Life Sciences"},{"orgOrder":0,"company":"BravoVax","sponsor":"GeoVax Labs","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BravoVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BravoVax \/ GeoVax Labs","highestDevelopmentStatusID":"1","companyTruncated":"BravoVax \/ GeoVax Labs"},{"orgOrder":0,"company":"Axon Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CYPRUS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Axon Neuroscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axon Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Axon Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Ciloa","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Exosome-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ciloa","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Ciloa \/ Bpifrance","highestDevelopmentStatusID":"1","companyTruncated":"Ciloa \/ Bpifrance"},{"orgOrder":0,"company":"Pasteur Institute","sponsor":"Vingroup Innovation Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pasteur Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasteur Institute \/ Vingroup Innovation Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Pasteur Institute \/ Vingroup Innovation Foundation"},{"orgOrder":0,"company":"Sanofi","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"SARS Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Sanofi \/ BARDA"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"Dyadic International, Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"rVaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Israel Institute for Biological Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Israel Institute for Biological Research \/ Dyadic International, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Israel Institute for Biological Research \/ Dyadic International, Inc"},{"orgOrder":0,"company":"ReiThera","sponsor":"Univercells","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Adenoviral Vector-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"ReiThera \/ Univercells"},{"orgOrder":0,"company":"NEC Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"NEC Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NEC Corporation \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NEC Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Peptide Based-pan Coronavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ImmunoScape","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoScape \/ Valo Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"ImmunoScape \/ Valo Therapeutics"},{"orgOrder":0,"company":"Proteona","sponsor":"Flinders University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Proteona","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteona \/ Flinders University","highestDevelopmentStatusID":"1","companyTruncated":"Proteona \/ Flinders University"},{"orgOrder":0,"company":"GSK","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"GSK \/ CEPI"},{"orgOrder":0,"company":"Open Orphan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"OC43 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Open Orphan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Open Orphan \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Open Orphan \/ Inapplicable"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19-Adenovirus Vector-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Valo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Exelead","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exelead","amount2":0.78000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.78000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Exelead \/ Merck & Co","highestDevelopmentStatusID":"1","companyTruncated":"Exelead \/ Merck & Co"},{"orgOrder":0,"company":"Seagull Biosolutions","sponsor":"The Union Science and Technology Ministry of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Active Virosome Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Seagull Biosolutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seagull Biosolutions \/ The Union Science and Technology Ministry of India","highestDevelopmentStatusID":"1","companyTruncated":"Seagull Biosolutions \/ The Union Science and Technology Ministry of India"},{"orgOrder":0,"company":"AnGes","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AnGes \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AnGes \/ Inapplicable"},{"orgOrder":0,"company":"SmartPharm Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Gene Encoded Antibody Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SmartPharm Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SmartPharm Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"SmartPharm Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Vaccine and Immunotherapy Center","sponsor":"Voltron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Self-Assembling Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vaccine and Immunotherapy Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaccine and Immunotherapy Center \/ Voltron Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Vaccine and Immunotherapy Center \/ Voltron Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Spicona","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"VLP Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Spicona","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Spicona"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"2019-nCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Inapplicable"},{"orgOrder":0,"company":"Oakwood Laboratories","sponsor":"Flow Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"FlowVax COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Oakwood Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oakwood Laboratories \/ Flow Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Oakwood Laboratories \/ Flow Pharma"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Soligenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"CoVaccine HT","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BTG Specialty Pharmaceuticals \/ Soligenix","highestDevelopmentStatusID":"1","companyTruncated":"BTG Specialty Pharmaceuticals \/ Soligenix"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"The University of Pittsburgh School of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Griffith University","sponsor":"Indian Immunologicals Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"SARS \u2013 CoV-2 Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Griffith University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Griffith University \/ Indian Immunologicals Limited","highestDevelopmentStatusID":"1","companyTruncated":"Griffith University \/ Indian Immunologicals Limited"},{"orgOrder":0,"company":"EpiVax","sponsor":"Generex Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Li-Key Peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVax \/ Generex Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ Generex Biotechnology"},{"orgOrder":0,"company":"EpiVax","sponsor":"Intravacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"OMV-peptide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiVax \/ Intravacc","highestDevelopmentStatusID":"1","companyTruncated":"EpiVax \/ Intravacc"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"nCoV-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"1","companyTruncated":"Baylor College of Medicine \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"iBio","sponsor":"CC-Pharming","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Plant Derived Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"iBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iBio \/ CC-Pharming","highestDevelopmentStatusID":"1","companyTruncated":"iBio \/ CC-Pharming"},{"orgOrder":0,"company":"Noachis Terra","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"Terra CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Noachis Terra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noachis Terra \/ Oragenics","highestDevelopmentStatusID":"1","companyTruncated":"Noachis Terra \/ Oragenics"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Medical Research Future Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Medical Research Future Fund","highestDevelopmentStatusID":"1","companyTruncated":"University of Melbourne \/ Medical Research Future Fund"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"AdaptVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"SARS-CoV-2 Capsid-Virus-like Particle Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ AdaptVac","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biologics \/ AdaptVac"},{"orgOrder":0,"company":"AGC Biologics","sponsor":"Takara Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Plasmid Dna Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AGC Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AGC Biologics \/ Takara Bio","highestDevelopmentStatusID":"1","companyTruncated":"AGC Biologics \/ Takara Bio"},{"orgOrder":0,"company":"Intravacc","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Inactivated EV D68 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Intravacc","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Intravacc \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"Intravacc \/ National Institutes of Health"},{"orgOrder":0,"company":"Soligenix","sponsor":"University Of Hawai'I At Manoa","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Filovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Soligenix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soligenix \/ University Of Hawai\\'I At Manoa","highestDevelopmentStatusID":"1","companyTruncated":"Soligenix \/ University Of Hawai\\'I At Manoa"},{"orgOrder":0,"company":"VaxEquity","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"saRNA Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"VaxEquity","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VaxEquity \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"VaxEquity \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"SK Bioscience","amount2":0.14000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"1","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"Achilles Vaccines","sponsor":"The EU Malaria Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Malaria Vaccine","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Achilles Vaccines","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Achilles Vaccines \/ The EU Malaria Fund","highestDevelopmentStatusID":"1","companyTruncated":"Achilles Vaccines \/ The EU Malaria Fund"},{"orgOrder":0,"company":"Ehime University","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"mRNA Vaccine","moa":"CD4 T-cell","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Ehime University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ehime University \/ GHIT Fund","highestDevelopmentStatusID":"1","companyTruncated":"Ehime University \/ GHIT Fund"},{"orgOrder":0,"company":"Evidation Health","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Evidation Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evidation Health \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Evidation Health \/ Sanofi"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"University of Georgia Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TFF Pharmaceuticals \/ University of Georgia Research Foundation","highestDevelopmentStatusID":"1","companyTruncated":"TFF Pharmaceuticals \/ University of Georgia Research Foundation"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"9-Valent HPV Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Weill Cornell Medicine","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Weill Cornell Medicine \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"1","companyTruncated":"Weill Cornell Medicine \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Valneva","sponsor":"Batavia Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Batavia Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Valneva \/ Batavia Bioscience"},{"orgOrder":0,"company":"George Mason University","sponsor":"Gylden Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Set-Point Vaccines","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"George Mason University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"George Mason University \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"1","companyTruncated":"George Mason University \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"University of Adelaide","sponsor":"Enesi Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Adelaide","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Transcutaneous Injection","sponsorNew":"University of Adelaide \/ Enesi Pharma Limited","highestDevelopmentStatusID":"1","companyTruncated":"University of Adelaide \/ Enesi Pharma Limited"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Human Biome S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medical University of Warsaw \/ Human Biome S.A.","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Warsaw \/ Human Biome S.A."},{"orgOrder":0,"company":"University of Calgary","sponsor":"Alberta Precision Laboratories | Alberta Health services | University of Alberta","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CMV-VST","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Alberta Precision Laboratories | Alberta Health services | University of Alberta","highestDevelopmentStatusID":"1","companyTruncated":"University of Calgary \/ Alberta Precision Laboratories | Alberta Health services | University of Alberta"},{"orgOrder":0,"company":"Pleuran, s.r.o.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Imunoglukan P4H","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pleuran, s.r.o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Pleuran, s.r.o. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Pleuran, s.r.o. \/ Undisclosed"},{"orgOrder":0,"company":"Vedic Lifesciences Pvt. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Microorganism","year":"2025","type":"Inapplicable","leadProduct":"Propionibacterium Freudenreichii P.UF1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vedic Lifesciences Pvt. Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedic Lifesciences Pvt. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences Pvt. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Bioithas SL","sponsor":"Centro Sperimentale del Latte S.r.l.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Lacticaseibacillus Rhamnosus CRL1505","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bioithas SL","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bioithas SL \/ Centro Sperimentale del Latte S.r.l.","highestDevelopmentStatusID":"1","companyTruncated":"Bioithas SL \/ Centro Sperimentale del Latte S.r.l."},{"orgOrder":0,"company":"PT Royal Medikalink Pharmalab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Lactiplantibacillus Plantarum DAD-13","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"PT Royal Medikalink Pharmalab","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PT Royal Medikalink Pharmalab \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"PT Royal Medikalink Pharmalab \/ Undisclosed"},{"orgOrder":0,"company":"Vitae Health Innovation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Beta Glucan","moa":"Beta-glucan receptor","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Vitae Health Innovation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vitae Health Innovation \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vitae Health Innovation \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Analyze & Realize"},{"orgOrder":0,"company":"Jiangsu Kanion Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Reduning","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Jiangsu Kanion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Kanion Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Jiangsu Kanion Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Huiyu Pharmaceutical","sponsor":"Changsha King-eagle Med Technology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sichuan Huiyu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sichuan Huiyu Pharmaceutical \/ Changsha King-eagle Med Technology","highestDevelopmentStatusID":"1","companyTruncated":"Sichuan Huiyu Pharmaceutical \/ Changsha King-eagle Med Technology"},{"orgOrder":0,"company":"RSUP Persahabatan","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"RSUP Persahabatan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RSUP Persahabatan \/ Otsuka Holdings","highestDevelopmentStatusID":"1","companyTruncated":"RSUP Persahabatan \/ Otsuka Holdings"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Human Biome Institute | Medical Research Agency Poland","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medical University of Warsaw \/ Human Biome Institute | Medical Research Agency Poland","highestDevelopmentStatusID":"1","companyTruncated":"Medical University of Warsaw \/ Human Biome Institute | Medical Research Agency Poland"}]

    Find Novel Drugs for Infections and Infectious Diseases under Development in UNITED STATES

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bioiberica

                            Spain
                            ABIM
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioiberica Joins a European Project to Develop Treatments for Complex Wounds

                            Details : Aim is to develop innovative multifunctional biomaterials to heal wounds using affordable EU-based manufacturing technologies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 18, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Bioiberica Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : DNDi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services and DNDi To Explore Joint Opportunities to Develop ...

                            Details : MoU aims to bring together DNDi’s expertise in NTDs with the scientific, technical and commercial capabilities of APSL and Dr. Reddy’s. The parties will explore a potential collaboration to develop and market novel and improved drugs for the treatmen...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 30, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : DNDi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Evonik

                            Germany
                            CPhI WW Frankfurt
                            Booth #5.1A24
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEvonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : BARDA

                            Deal Size : $220.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Evonik Invests US$220 Million in Partnership with The U.S. Government to Build New Lipid Production Facility F...

                            Details : Lipids, molecules that make up the building blocks of living cells, are critical to producing mRNA-based drugs. The mRNA is enclosed in a lipid nanoparticle (LNP) composed of specific lipids. The LNP protects the mRNA and delivers it safely into the cell...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 06, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : BARDA

                            Deal Size : $220.0 million

                            Deal Type : Funding

                            Evonik company banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alchem International Private Ltd

                            India
                            Vitafoods
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothAlchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

                            Lead Product(s) : Curcuminoid,Ellagic acid,Gingerol

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : AIIMS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AIIMS Patna Confirms efficacy of AlchemLife’s Phytorelief a Natural Anti-Viral for Mild to Moderate Covid-19...

                            Details : After ten days of treatment with Phytorelief along with standard management, 83% of Covid-19 patients, with mild or moderate symptoms, turned negative in a trial conduct in AIIMS Patna.

                            Product Name : Phytorelief-CC

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            October 06, 2021

                            Lead Product(s) : Curcuminoid,Ellagic acid,Gingerol

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : AIIMS

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Alchem

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AbbVie Inc

                            U.S.A
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lopinavir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : European Health Authorities

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            AbbVie Partnering with Global Authorities

                            Details : The company is collaborating with select health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of lopinavir/ritonavir against COVID-19.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 03, 2020

                            Lead Product(s) : Lopinavir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : European Health Authorities

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sanofi to Enroll Thousands for its Coronavirus Vaccine Trials

                            Details : Sanofi is working on two vaccine projects to prevent COVID-19. Of more than 100 vaccine candidates in development, 10 have reached the clinical testing stage so far.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 05, 2020

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sanofi and Gsk to Join Forces in Unprecedented Vaccine Collaboration to Fight Covid-19

                            Details : Sanofi will contribute its S-protein COVID-19 antigen and GSK will contribute its proven pandemic adjuvant technology to the collaboration.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 14, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : GSK

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19

                            Details : Translate Bio will use its mRNA platform to discover, design, and manufacture a range of SARS-CoV-2 vaccines. Sanofi will provide deep expertise and support from its external research networks.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 27, 2020

                            Lead Product(s) : mRNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AbbVie Inc

                            U.S.A
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lopinavir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie’s HIV drug combo shows no benefit in Covid-19 trial

                            Details : The primary endpoint was the time to clinical improvement. The medication failed to improve the condition or prevent the death of severely-affected Covid-19 patients, compared to standard care.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 19, 2020

                            Lead Product(s) : Lopinavir,Ritonavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : SARS Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : BARDA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sanofi joins forces with U.S. Department of Health for COVID-19

                            Details : Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            February 18, 2020

                            Lead Product(s) : SARS Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : BARDA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth